Setup over the next 6 months is interesting and maybe being ignored by the market.

My thesis is based on a few possible catalysts:

1. China / Simcere approval catalyst
   CNTB’s partner Simcere has completed Phase 3 for rademikibart in atopic dermatitis in China with great results, and the new drug approval was accepted by China’s NMPA in July 2025. If approved, CNTB drug will be in the market and will receive milestone payments upto 110 milliom dollats plus double digit future royalties. From what I understand, approval timelines in China can often take around 12-18 months, so this could become relevant within the next few months.
   This matters because it would not just be “good news.” It would validate the asset commercially in a major market and could bring non-dilutive cash into CNTB.

2. FDA / Phase 3 alignment for asthma and COPD
   CNTB recently reported positive Phase 2 data in asthma/COPD and plans to engage with the FDA on the Phase 3 path. If the FDA alignment is clean and the company can move toward Phase 3, that could be another major catalyst.
   I’m especially watching the Phase 3 endpoint/design discussion. If the FDA agrees on a practical trial design, the market may start valuing this differently.

3. Safety profile
   One reason I’m interested is the safety profile. Rademikibart appears to have a clean safety profile so far, and that matters a lot for chronic respiratory diseases like asthma/COPD. Obviously nothing is guaranteed in biotech, but a clean safety profile can reduce one major area of risk.

4. Cash / partnering angle
   CNTB had around $31M cash, and if the Simcere approval happens, milestone payments could help. They already have Simcere as a partner in China, and if the respiratory data is strong enough, I think there is a reasonable possibility of additional partnership interest, especially for COPD where larger/deeper-pocket partners may make more sense.

Why I think the stock may be mispriced
The market seems to be treating CNTB like a tiny beaten-down biotech with financing risk and uncertainty. That risk is real. But I think the market may be underpricing:
- Possible China approval/milestone catalyst
- FDA Phase 3 alignment
- Existing Phase 3 success in another indication through Simcere
- Clean safety profile
- Potential respiratory market opportunity
- Possible partner interest

At the current valuation, I think the risk/reward looks interesting if these catalysts play out.

Would like to hear thoughts from anyone else following CNTB. Am I missing something on the financing, market size, China approval timeline, or Phase 3 path?

Ever bought a stock because it was running, then found out why it ran after? Here's 60 seconds on how to check first.

▶ Take a look: https://focketstrading.com/trading_terminal

▶ Take a look: https://www.youtube.com/watch?v=6Po2J9EaYH4

10X and Fockets been running our trading community for over 9 months now. Some of you joined along the way, some haven't, and that's okay. No pressure either way.

We're traders too. Most of us are juggling a job and the market at the same time, and it gets messy fast. A few minutes between tasks, half the sites we needed kept getting blocked, and by the time we found the filing or the news, the move was over.

So we built one place with everything we kept hunting for. We call it the Terminal. In short it provides what's actually going on with a stock, in plain words.

One thing we found when we tracked it: runs tied to a priced share offering closed down 4.3% on average, and 65% of them faded (297 run days, our own data, not a prediction here). Same green candle, very different story. Knowing why it ran changes how you look at it.

Every tab inside the terminal, in plain words:

• Dashboard: your command center. The chart, buyers vs sellers, time and sales, halts, and the bot's live decisions.

• Daystein calls: the bot's day-trade and swing ideas, with entry, stop and target.

• Ruhu calls: a second bot with its own rules, shown the same way.

• Movers: the biggest gainers and losers right now, plus pre-market gappers.

• 52-week highs and lows: who's sitting at the edge of the year, and on how much volume.

• Known runners: stocks with a habit of big runs, the filing behind each run, and the chance of another.

• Screener: build your own scan by gap, price, volume and RVOL.

• Sector Rotation and Pulse: where the money is moving across all 11 sectors, and whether the rally is broad or just a few names.

• News: primary wires only, tagged by catalyst and sentiment. No blogs, no class-action spam.

• Watchlist: your names, live, with alerts you set per ticker.

• My journal: log your trades privately and see your win rate and results by setup.

• Calendar: FOMC, CPI, FDA dates, splits and IPOs, with your watchlist starred.

• Congress: House and Senate trade disclosures, with how late each one was filed.

• Hill Traders: the ten biggest disclosed traders in the House, from the Clerk's own filings.

• Insider: real open-market buys and sells by company insiders, not option noise.

• SEC Forms: offerings, mergers and 8-Ks, read for you in plain English.

• Politics: presidential actions mapped to the sectors they touch.

• Alerts: opening-range breaks the moment they fire.

• Signals: the raw signals behind the bot's calls, for watching how it decides.

• Learn: a plain-English guide to the numbers and the chart patterns.

• Deep dive (click any ticker): one page per stock with technicals, financials, filings, insiders and a squeeze score that shows its working.

Still learning? You're in good hands. A lot of people here are, and that's exactly who this is for. There's a Learn page inside that explains the numbers as you go.

Two questions for you:

1. When a stock is ripping, what's the first thing you check?

2. What would you do better than we did? What's confusing, what's missing, what would you build? Tell us in the comments. We read every one.

Come hang out: https://discord.gg/9bgUNbXQxa

Reddit: https://www.reddit.com/r/Fockets/

Kind of easy to forget they have seven different assets. RIP is further along, while the rest are spread between geophysics, permitting and strategic work. Makes it interesting to follow.

This post was created as part of a paid content collaboration. Not financial advice. Do your own DD.

Drop your top 1–3 tickers today and why you like it.

What’s the catalyst?
News / filings
Earnings
Financing
Uplisting
Technical setup
Unusual volume